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Abstract 
Inborn errors of metabolism are inherited biochemical disorders
caused by lack of a functional enzyme, transmembrane trans-
porter, or similar protein, which then results in blockage of the
corresponding metabolic pathway. Taken individually, inborn
errors of metabolism are rare. However, as a group these diseases
are relatively frequent and they may account for most of neonatal
mortality and need of health resources. The detection of genetic
metabolic disorders should occur in a pre-symptomatic phase.
Recently, the introduction of the tandem mass spectrometric
methods for metabolite analysis has changed our ability to detect
intermediates of metabolism in smaller samples and provides the
means to detect a large number of metabolic disorders in a single
analytical run. Screening panels now include a large number of
disorders that may not meet all the criteria that have been used as
a reference for years. The rationale behind inclusion or exclusion
of a respective disorder is difficult to understand in most cases
and it may impose an ethical dilemma. The current organization
is an important tool of secondary preventive medicine, essential
for children’s healthcare, but the strong inhomogeneity of the
regional models of screening applied today create in the Italian
neonatal population macroscopic differences with regards to
healthcare, which is in effect mainly diversified by the newborn’s
place of birth, in possible violation of the universal criterion of
the equality of all citizens. Carefully weighed arguments are
urgently needed since patient organizations, opinion leaders and
politicians are pressing to proceed with expansion of neonatal
population screening.
Riassunto
Gli errori congeniti del metabolismo sono malattie ereditarie
causate dalla carenza di un enzima funzionale, trasportatore trans-
membrana o proteina, che si traduce poi in blocco della via meta-
bolica corrispondente. Gli errori congeniti del metabolismo, presi
singolarmente, sono rari. Tuttavia, come gruppo queste malattie
sono relativamente frequenti e spesso caratterizzate da alta inciden-
za di mortalità neonatale. La diagnosi, pertanto, dovrebbe avvenire
in una fase pre-sintomatica. Recentemente, l’introduzione di meto-
di di spettrometria di tandem massa per le analisi dei metaboliti ha
cambiato la nostra capacità di rilevare metaboliti in piccoli campi-
oni ed ha fornito i mezzi per rilevare un gran numero di malattie
metaboliche in un’unica seduta analitica. I pannelli di screening
includono, ad oggi, un gran numero di disturbi che non soddisfano
i criteri utilizzati come riferimento per anni. Il razionale alla base
dell’inclusione o dell’esclusione di un rispettivo disordine è difficile
da definire nella maggior parte dei casi e può imporre un dilemma
etico. L’attuale organizzazione è un importante strumento di medi-
cina preventiva secondaria, indispensabile per la salute dei bambini,
ma la forte disomogeneità dei modelli regionali di screening appli-
cati oggi crea, nella popolazione italiana neonatale, macroscopiche
differenze per quanto riguarda le cure, che sono effettivamente
diversificate in base al luogo di nascita del neonate, in possibile vio-
lazione del criterio universale della parità di tutti i cittadini. Un
approfondito dibbatito in tal senso, è urgentemente necessario
poiché le organizzazioni di pazienti, mezzi di informazione e parte
dei rappresentanti politici pressano per l’espansione dello screening
nella popolazione neonatale. 
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Scientific and historical background
The congenital disorders associated with growth retardation
and/or intellectual disabilities may recognize different etiologies:
environmental and genetic causes among which metabolic dis-
eases, monogenic diseases,1 syndromes, submicroscopic chromo-
somal aberrations. Recently, the introduction of modern tech-
niques such as array-CGH2 and tandem mass spectrometric meth-
ods for metabolite analysis has changed our ability to detect inter-
mediates of metabolism in smaller samples and provides the
means to detect a large number of metabolic disorders in a single
analytical run.
Inborn errors of metabolism are permanent and inherited bio-
chemical disorders, also sometimes known as inherited metabolic
diseases. The term inborn errors of metabolism was coined in the
early 1900s by Garrod,3 who described the first alkaptonuria.  In
general, an inborn error of metabolism is caused by lack of a func-
tional enzyme, transmembrane transporter, or similar protein,
which then results in blockage of the corresponding metabolic
pathway. There may be accumulation of metabolites prior to the
metabolic block, and/or deficiency in the ultimate product(s) of
the pathway. Both may provide a means of therapeutic interven-
tion, either by restricting the supply of precursors to the pathway
or by supplying a missing product, or both. Approximately half of
all inborn errors of metabolism can be treated biochemically,
although the success of such treatment is variable. Taken individ-
ually, inborn errors of metabolism are rare. However, as a group
these diseases are relatively frequent and collectively their inci-
dence may approach 1 in 800 to 2500 births.4 Their collective
importance is growing and they occupy a significant place in the
practice of paediatrics and in general medicine, because clinical
presentation may occur in any age group, from fetuses and new-
born to adulthood. Neonatal onset is common because the early
neonatal period is a time of prevalent catabolism.4 Many impor-
tant molecules, produced at birth, are likely involved in early-
onset and late-onset diseases and their role in complex metabolic
pathways is currently investigated.6,7 Together with prematurity,8,9
infections10-13 and congenital malformations,14-16 inborn errors of
metabolism may account for most of neonatal morbidity/mortal-
ity and need of health resources. The detection of genetic meta-
bolic disorders should occur very early in life, in a presymptomatic
phase, before health, growth and neuromotor development could
be affected by the metabolic error. In the early 1960s, Guthrie
developed the first method applicable to whole population screen-
ing for phenylketonuria (PKU).17 In this assay, he measured
phenylalanine in blood spots on filter paper using a bacterial inhi-
bition assay. Since it was instituted the first newborn screening
program for PKU in 1962, it was already recognized that early
detection of the disease and early introduction of a diet, poor in
phenylalanine resulted in a significant decrease in morbidity as
well as significant savings of medical costs.18 The criteria for inclu-
sion of a new disease test into a newborn screening program con-
tinue to evolve. Currently the disorders included in most newborn
screening programs essentially meet defined criteria, summarized
in table 1.19 Phenylketonuria (PKU) serves as an excellent exam-
ple of a metabolic disorder that fulfills these criteria. The inci-
dence of PKU is about 1 in 14.000 in USA, 1 in 10.000 in Italy.
The phenotype is well defined. The natural history of the untreat-
ed disease is characterized by a severe neurodegenerative course,
but early diagnosis and treatment significantly improve the out-
come.20 Based on the success of the screening for PKU, programs
have been extended with the same benefit to other conditions
(congenital hypothyroidism, congenital adrenal hyperplasia, etc.)
during the later decades of the twentieth century.21 More recently,
newborn screening and genetic testing have expanded rapidly
with the advent of multiplex and/or DNA technologies. Until the
late 1990s, screening tests were relatively simple and inexpensive.
Recently, the introduction of the tandem mass spectrometric
methods for metabolite analysis has changed our ability to detect
intermediates of metabolism in smaller samples and it has sup-
plied greater efficiency with fewer tests.22 Expanded newborn
screening with Tandem Mass Spectrometry (MS/MS) provides the
means to detect a large number of metabolic disorders in a single
analytical run. Screening panels now include a large number of
disorders that may not meet all the criteria that have been used as
a reference for years.
State of the art
In many countries, such expansion of newborn screening (NBS)
programs has been driven by technological advances, public pres-
sure (lobbying of advocacy groups), the entry of large private lab-
oratories providing NBS services, and international recommen-
dation with the aim of harmonization of national plans for rare
diseases.23 In 2005, the American College  of Genetics and
Genomics24 recommended 29 core disorders for which they
found evidence of benefit. The disorders chosen to be included
in European newborn screening programs differ considerably.
Given that all European populations and also largely the USA
have a common genetic background, the reason for these differ-
ences cannot be explained by major differences in disease preva-
lence but only by different approaches to the estimation of risks
and benefits. In the most restrictive European countries, only
medium chain acyl dehydrogenase deficiency (MCADD) is
screened in addition to PKU (UK, Switzerland). Twenty disor-
ders are screened in NBS program of Austria.25 In Germany,
where extended screening started in 1999, health authorities
decided in 2005 to limit the number of metabolic disorders to be
detected by MS/MS to 10 and decided that all analytes that are
not needed for this purpose have to be suppressed or deleted
immediately after the analysis. The disorders that have been
omitted include some conditions that are regarded as non-dis-
eases or at least as biochemical abnormalities with doubtful
pathological meaning. 3-Methylcrotonyl carboxylase deficiency,
thought to be a rare disorder with severe neurological pathology,
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had been detected in an appreciable number of newborns and in
their clinically unaffected mothers.26 Therefore, the disorder has
been excluded from the German panel. The rationale behind
inclusion or exclusion of a respective disorder is difficult to
understand in most cases. In some cases this restriction may
impose an ethical dilemma. The more global approach of screen-
ing for all of the potentially detectable conditions, while partial-
ly neglecting the classical screening criteria, burdens the health
care system and the affected individuals. It was shown that false-
positive results by expanded screening may cause disruption of
family life through a combination of unnecessary hospitaliza-
tions, high parental stress, and parent–child relationship dys-
function.27 Part of the decision concerning inclusion of certain
disorders depends on organizational and timing differences
among different countries. In the UK the recommended date for
taking the blood sample is the 5th day of life, whereas in the
USA, in Germany or in Italy the blood sample is obtained by the
2nd day of life with the result being available at the 3rd to 5th
day of life, enabling early intervention.  It seems clear that in the
UK the most common organic acidurias, methylmalonic aciduria
and propionic aciduria, may manifest their symptoms before the
screening sample is taken or before the result will be available,
without benefit of the NBS program to the patient.28
Considering the complexity of decisions, it is hoped that screen-
ing policies will become standardized between European coun-
tries, and of course also between screening centres within one
country, with regard to all aspects of analytical and organization-
al steps in the process of newborn screening. Increasing knowl-
edge about the natural course of diseases and their variants, new
treatment options, and analytical developments improving sensi-
tivity and/or specificity of screening tests are some of the reasons
for the necessity to re-assess expanded screening for additional
disorders. Timely and aggressive treatment may change the out-
come in some diseases which were previously classified as non-
treatable conditions, thus justifying the inclusion of, in example
glutaric aciduria type I, as a screening disease.29 Common pro-
jects for quality control and assessment, as well as expert medical
judgement, are urgently needed at a European level and should
result in standardization of the screening panels and of the spec-
trum of analysed metabolites, as well as in suggestions for the
sizes of screening laboratories, analytical procedures, follow-up
management and proficiency and quality testing. In Italy neona-
tal screening program has been mandatory for congenital
hypothyroidism, cystic fibrosis, and phenylketonuria since 1992.
Moreover, on the basis of regional laws other screening programs
for endocrinopathies and inborn errors of metabolism are per-
formed in some Italian Regions. This implies that every year
about 550.000 dried blood spot (DBS) cards from all Italian
newborns are collected and analyzed in the 32 Screening Centers
active in our country. A recent survey performed by the Italian
Society for the Study of Metabolic Diseases and Neonatal
Screening (SIMMESN) revealed a significant dishomogeneity
among screening laboratories in the management of residual DBS
in terms of time of retention, requirement of parental consent
and use of the samples, and this dishomogeneity created impor-
tant ethical issues. In order to achieve an appropriate balance
between respecting the rights of newborns and their parents ver-
sus the potential for public good deriving from the use of DBS
for research purposes, the Joint Group National Committee of
Bioethics - National Committee for Biosafety Biotechnologies
and Life Sciences have recommended developing a National
Network of Regional Newborn Screening Repositories for collec-
tion of residual DBS, coordinated by the Italian National
Institute of Health.30




have a significant incidence in the population screened
are clinically well defined with the untreated natural history characterized;
have a well-defined biochemical phenotype;
cause significant morbidity and/or mortality;
are treatable, where treatment improves outcome;
testing is safe, simple and sufficiently sensitive;
specific confirmatory testing is available;
testing, treatment and treatment outcome are cost effective with respect to non-treatment
Table 2
ITALIAN REGIONS IN WHICH A PROGRAM OF EXPANDED  NEWBORN SCREENING IS ACTIVE 
OR ASSESSMENT OF FEASIBILITY PROJECTS IS ONGOING.
Region Description of expanded newborn screening programme
Tuscany regional programme of expanded  newborn screening, in line with the specific legislative decree of the Tuscany region. 
Liguria pilot regional programme of expanded  newborn screening, with the collection of the parentsʼ informed consent, 
approved by the regional healthcare authorities.  
Lazio pilot subregional programme of  expanded newborn screening.
Veneto, Emilia Romagna, Sicily dissemination of regional deliberations for the activation in a near future of programmes of expanded newborn screening. 
Lombardy, Marche, Campania there are currently assessments of projects of feasibility, not yet approved or activated by the competent regional Authorities. 
Future perspectives
As highlighted in the annual reports of the Italian Society of
Neonatal Screening (SISN), in our Country there are 32 active
Centres of Neonatal Screening, with a very diversified pool of
patients according to area size (Sub-regional, Regional, Inter-
regional) and number of samples (from < 5,000 born/year to >
100,000 born/year), 22 of them at the moment carrying out differ-
ent regional programs, according to the local organization, defined
by the competent regional Authority. It is clear that the current
organization is an important tool of secondary preventive medicine,
essential for children’s healthcare, but the strong inhomogeneity of
the regional models of screening applied today, for the profound
differences in the composition of the panel of screened pathologies,
create in the Italian neonatal population (in possible violation of the
universal criterion of the equality of all citizens) macroscopic dif-
ferences with regards to healthcare, which is in effect mainly diver-
sified by the newborn’s place of birth. It is also important to stress
how the careful reading of the scientific documentation issued by
the SISN-SISMME Society highlights also a considerable further
inhomogeneity due to the organization and technical management
of each single regional screening program, with numerous indica-
tors (catchment area, cut-off values, recall index, analytical strate-
gies of selection, efficiency index, etc.) presenting a discretional
variability that is not always justified by scientific evidence or by
strictly economy management reasons.31 Carefully weighed argu-
ments are urgently needed since patient organizations, opinion
leaders and politicians are pressing to proceed with expansion of
neonatal population screening. In addition to disorders of amino
acid, organic acid and fatty acid oxidation metabolism, MS/MS
may help in screening newborns for other inborn errors of metabo-
lism. Recently, Li et al.32 demonstrated the utility of MS/MS in
measuring the lysosomal enzymes responsible for Gaucher, Fabry,
Neimann-Pick A/B, Pompe and Krabbe diseases. Additional groups
of disorders including lysosomal storage disorders33 and X-linked
adrenoleukodystrophy34 are awaiting implementation in diagnosis
and treatment. The national health care systems are especially inde-
pendent within the EU, thus a common political solution is not
expected and does not seem desirable. The annual regional
European meetings of the International Society of Newborn
Screening could provide the first informal platform to organize
Europe in respect of a voluntary basis.
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